{"id":21285,"date":"2023-03-08T14:47:00","date_gmt":"2023-03-08T06:47:00","guid":{"rendered":"https:\/\/flcube.com\/?p=21285"},"modified":"2025-01-11T14:57:43","modified_gmt":"2025-01-11T06:57:43","slug":"suzhou-porton-biologics-partners-with-bennu-biotherapeutics-for-gene-and-cell-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21285","title":{"rendered":"Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies"},"content":{"rendered":"\n

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a strategic partnership with compatriot firm Bennu Biotherapeutics, a T-cell therapy specialist based in Shanghai. The collaboration focuses on the area of gene and cell therapies (GCTs), with Porton providing comprehensive CDMO services to Bennu. The agreement covers a range of services including plasmids, viruses, TIL, TCR-T, and Treg cells, among others. Financial details of the partnership were not disclosed.<\/p>\n\n\n\n

About Suzhou Porton Biologics<\/strong>
Founded in 2018, Suzhou Porton Biologics has established itself as a leading end-to-end CGT CDMO service provider. The company’s platform covers a broad spectrum of therapeutic areas, including plasmids, cell therapies, gene therapies, oncolytic viruses, nucleic acid therapies, live bacterial therapies, and more. This comprehensive service offering positions Porton as a key player in the development and manufacturing of advanced therapies.<\/p>\n\n\n\n

About Bennu Biotherapeutics<\/strong>
Bennu Biotherapeutics is a Shanghai-based specialist in T-cell therapies, focusing on the development of innovative cell therapies targeting tumor and autoimmune diseases. The partnership with Porton Biologics will enhance Bennu’s capabilities in bringing these therapies to market, leveraging Porton’s extensive experience and infrastructure in CDMO services.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3123,30,16,77,19,628],"class_list":["post-21285","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-bennu-biotherapeutics","tag-biotech","tag-cancer","tag-cell-therapy","tag-cro-cmo-cdmo","tag-porton-biologics"],"yoast_head":"\nSuzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a strategic partnership with compatriot firm Bennu Biotherapeutics, a T-cell therapy specialist based in Shanghai. The collaboration focuses on the area of gene and cell therapies (GCTs), with Porton providing comprehensive CDMO services to Bennu. The agreement covers a range of services including plasmids, viruses, TIL, TCR-T, and Treg cells, among others. Financial details of the partnership were not disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21285\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21285\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-08T06:47:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-11T06:57:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21285#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21285\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies\",\"datePublished\":\"2023-03-08T06:47:00+00:00\",\"dateModified\":\"2025-01-11T06:57:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21285\"},\"wordCount\":206,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Bennu Biotherapeutics\",\"Biotech\",\"Cancer\",\"Cell-therapy\",\"CRO \\\/ CMO \\\/ CDMO\",\"Porton Biologics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21285#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21285\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21285\",\"name\":\"Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-03-08T06:47:00+00:00\",\"dateModified\":\"2025-01-11T06:57:43+00:00\",\"description\":\"China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a strategic partnership with compatriot firm Bennu Biotherapeutics, a T-cell therapy specialist based in Shanghai. The collaboration focuses on the area of gene and cell therapies (GCTs), with Porton providing comprehensive CDMO services to Bennu. The agreement covers a range of services including plasmids, viruses, TIL, TCR-T, and Treg cells, among others. Financial details of the partnership were not disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21285#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21285\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21285#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies - Insight, China's Pharmaceutical Industry","description":"China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a strategic partnership with compatriot firm Bennu Biotherapeutics, a T-cell therapy specialist based in Shanghai. The collaboration focuses on the area of gene and cell therapies (GCTs), with Porton providing comprehensive CDMO services to Bennu. The agreement covers a range of services including plasmids, viruses, TIL, TCR-T, and Treg cells, among others. Financial details of the partnership were not disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21285","og_locale":"en_US","og_type":"article","og_title":"Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=21285","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-03-08T06:47:00+00:00","article_modified_time":"2025-01-11T06:57:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21285#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21285"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies","datePublished":"2023-03-08T06:47:00+00:00","dateModified":"2025-01-11T06:57:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21285"},"wordCount":206,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Bennu Biotherapeutics","Biotech","Cancer","Cell-therapy","CRO \/ CMO \/ CDMO","Porton Biologics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21285#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21285","url":"https:\/\/flcube.com\/?p=21285","name":"Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-03-08T06:47:00+00:00","dateModified":"2025-01-11T06:57:43+00:00","description":"China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a strategic partnership with compatriot firm Bennu Biotherapeutics, a T-cell therapy specialist based in Shanghai. The collaboration focuses on the area of gene and cell therapies (GCTs), with Porton providing comprehensive CDMO services to Bennu. The agreement covers a range of services including plasmids, viruses, TIL, TCR-T, and Treg cells, among others. Financial details of the partnership were not disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21285#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21285"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21285#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21285","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21285"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21285\/revisions"}],"predecessor-version":[{"id":21287,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21285\/revisions\/21287"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21285"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21285"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}